This study suggests that combination therapeutic strategies that use conventional chemotherapy to debulk tumor burden, followed by novel drugs such as histone deacetylation (HDAC) inhibitors and T cell immunotherapy, may eliminate residual chemoresistant tumor cells and help prevent disease relapse. This evidence concerns the gene HDAC9 and neoplasm.